Clinical trial
Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and…
NCT00284141 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00284141 |
|---|---|
| Title | Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma |
| Official title | A Multicenter, Open-label, Single-arm, Two-stage Study of the Efficacy and Safety of AVE0005 (VEGF Trap) Administered Intravenously Every 2 Weeks in Patients With Platinum- and Erlotinib-resistant Locally Advanced or Metastatic Non-small-cell Lung Adenocarcinoma |
| Lead sponsor | Sanofi, Industry |
| Collaborators | Regeneron Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pulmonary Diseases, Neoplasms, Lung |
| Intervention type | Drug |
| Interventions | Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®) |
| Enrollment | 98 |
| Start date | Jan 1, 2006 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jan 31, 2006 |
| Last update posted | Dec 10, 2012 |
| Countries | Canada, France, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: